The chemical class of "EFHC2 Inhibitors" comprises a diverse range of compounds, each characterized by its potential to influence cellular mechanisms or pathways that might indirectly affect the activity or expression of the EFHC2 protein. EFHC2, encoded by the EFHC2 gene, is implicated in various cellular processes, though its precise biological functions and interactions remain under investigation. The inhibitors listed do not interact directly with EFHC2 but are thought to target different signaling pathways and cellular processes that might modulate its function or expression.
Compounds like Lithium Chloride and Rapamycin, which are GSK-3 and mTOR inhibitors respectively, might modulate pathways that intersect with EFHC2's regulatory network. Trichostatin A, a histone deacetylase inhibitor, and 5-Azacytidine, a DNA methyltransferase inhibitor, can alter gene expression and DNA methylation patterns, respectively, potentially influencing genes related to EFHC2 or its regulatory mechanisms.
LY294002, a PI3K inhibitor, and PD98059, a MEK inhibitor, target key signaling routes in cell survival and differentiation, potentially altering pathways involving EFHC2. Forskolin, by increasing cAMP levels, and Y-27632, a Rho kinase inhibitor, modulate various cellular responses and stress pathways, which might have implications for the function or regulation of EFHC2. SB431542, a TGF-beta receptor inhibitor, targets specific cellular processes and pathways that might be related to EFHC2 function.
Staurosporine, a broad-spectrum kinase inhibitor, Bortezomib, a proteasome inhibitor, and Curcumin, known for its broad effects on cellular signaling, can influence a variety of pathways, potentially including those involving EFHC2.
This class of inhibitors is characterized by its indirect mode of action, targeting various signaling cascades and cellular processes to influence the activity or expression of EFHC2. Each inhibitor has distinct pharmacological properties and modes of action, reflecting the complexity of cellular signaling networks and the multifaceted nature of protein regulation within these networks. The diversity in this chemical class underscores the broad spectrum of molecular interactions and pathways that can be modulated to influence a specific protein's activity, such as EFHC2, in complex biological systems.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
GSK-3 inhibitor, potentially affecting signaling pathways that could intersect with EFHC2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, could influence autophagy and growth pathways related to EFHC2. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor, may alter gene expression potentially impacting EFHC2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, might affect cell survival and growth pathways involving EFHC2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, potentially altering MAPK/ERK signaling pathways involving EFHC2. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylyl cyclase, increasing cAMP levels, possibly affecting pathways involving EFHC2. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Rho kinase inhibitor, can affect cytoskeleton organization, potentially influencing EFHC2-related paths. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-beta receptor inhibitor, potentially impacting signaling pathways related to EFHC2. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor, could affect DNA methylation patterns linked to EFHC2. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Kinase inhibitor, might affect multiple signaling pathways related to EFHC2. | ||||||